Insmed Incorporated
INSM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -7.01 | -0.75 | -1.77 | -3.33 |
| FCF Yield | -0.73% | -1.10% | -1.97% | -1.64% |
| EV / EBITDA | -89.84 | -62.28 | -62.45 | -61.18 |
| Quality | ||||
| ROIC | -21.79% | -14.44% | -15.86% | -13.31% |
| Gross Margin | 58.74% | 73.86% | 77.08% | 74.96% |
| Cash Conversion Ratio | 0.59 | 0.64 | 1.02 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.76% | 13.89% | 13.96% | 14.02% |
| Free Cash Flow Growth | -6.28% | 23.19% | -34.23% | -9.83% |
| Safety | ||||
| Net Debt / EBITDA | -1.19 | 1.84 | -3.18 | -2.80 |
| Interest Coverage | -20.84 | -14.73 | -11.50 | -10.69 |
| Efficiency | ||||
| Inventory Turnover | 0.49 | 0.26 | 0.21 | 0.27 |
| Cash Conversion Cycle | 104.66 | 153.67 | 228.30 | 132.73 |